# Oral Pyrophosphate Absorption in PXE Disease

> **NCT04441671** · PHASE2 · WITHDRAWN · sponsor: **Tampere University Hospital**

## Conditions studied

- Pseudoxanthoma Elasticum

## Interventions

- **DRUG:** Disodium Pyrophosphate

## Key facts

- **NCT ID:** NCT04441671
- **Lead sponsor:** Tampere University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12-08
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-04-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn
- **Last updated:** 2021-04-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04441671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04441671, "Oral Pyrophosphate Absorption in PXE Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04441671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*